Perceptive Advisors Llc Sells 21,826 Shares of Rain Therapeutics Inc. (NASDAQ:RAIN) Stock

Rain Therapeutics Inc. (NASDAQ:RAIN) major shareholder Perceptive Advisors Llc sold 21,826 shares of the firm’s stock in a transaction on Monday, October 11th. The shares were sold at an average price of $12.51, for a total transaction of $273,043.26. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Perceptive Advisors Llc also recently made the following trade(s):

  • On Thursday, October 7th, Perceptive Advisors Llc sold 13,368 shares of Rain Therapeutics stock. The shares were sold at an average price of $14.81, for a total transaction of $197,980.08.

Shares of RAIN stock traded up $1.51 on Wednesday, hitting $15.06. 77,560 shares of the company’s stock traded hands, compared to its average volume of 129,237. Rain Therapeutics Inc. has a one year low of $11.57 and a one year high of $23.90. The firm’s fifty day moving average is $16.12.

Rain Therapeutics (NASDAQ:RAIN) last released its earnings results on Tuesday, August 10th. The company reported ($0.39) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.50) by $0.11. As a group, equities analysts predict that Rain Therapeutics Inc. will post -2.72 earnings per share for the current fiscal year.

RAIN has been the topic of several research reports. The Goldman Sachs Group cut shares of Rain Therapeutics to a “hold” rating and set a $22.00 price objective on the stock. in a research report on Tuesday, September 14th. Zacks Investment Research upgraded shares of Rain Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Piper Sandler restated an “overweight” rating and set a $25.00 price objective on shares of Rain Therapeutics in a research report on Tuesday, July 20th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, Rain Therapeutics currently has a consensus rating of “Buy” and an average price target of $25.25.

Institutional investors have recently made changes to their positions in the business. Victory Capital Management Inc. bought a new stake in Rain Therapeutics in the 2nd quarter worth $1,787,000. Lumina Fund Management LLC bought a new stake in Rain Therapeutics in the 2nd quarter worth $93,000. Monashee Investment Management LLC bought a new stake in shares of Rain Therapeutics during the 2nd quarter valued at about $311,000. Logos Global Management LP bought a new stake in shares of Rain Therapeutics during the 2nd quarter valued at about $12,126,000. Finally, Deutsche Bank AG bought a new stake in shares of Rain Therapeutics during the 2nd quarter valued at about $68,000. 57.18% of the stock is currently owned by institutional investors and hedge funds.

About Rain Therapeutics

Rain Therapeutics Inc, a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is RAIN-32, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing RAIN-32 that has completed Phase II clinical trial in liposarcoma, Phase I clinical trial in solid tumors, and Phase II clinical trial in intimal sarcoma, as well as RAD52 for tumors, including breast, ovarian, prostate, and other cancers.

Featured Story: How Does the Quiet Period Work?

Insider Buying and Selling by Quarter for Rain Therapeutics (NASDAQ:RAIN)

Receive News & Ratings for Rain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.